These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9425731)

  • 1. Immunotherapeutic potential of bispecific antibodies.
    van de Winkel JG; Bast B; de Gast GC
    Immunol Today; 1997 Dec; 18(12):562-4. PubMed ID: 9425731
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies.
    Deo YM; Graziano RF; Repp R; van de Winkel JG
    Immunol Today; 1997 Mar; 18(3):127-35. PubMed ID: 9078685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective silencing of autoreactive B lymphocytes-Following the Nature's way.
    Nikolova KA; Mihaylova NM; Voynova EN; Tchorbanov AI; Voll RE; Vassilev TL
    Autoimmun Rev; 2010 Sep; 9(11):775-9. PubMed ID: 20601201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE.
    Wang C; Pan HF; Ye DQ
    Autoimmun Rev; 2012 Mar; 11(5):373. PubMed ID: 21224014
    [No Abstract]   [Full Text] [Related]  

  • 5. Bispecific antibodies and diabodies for cancer immunotherapy.
    Elsässer-Beile U; Bühler P
    Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapeutic perspective for bispecific antibodies.
    van Spriel AB; van Ojik HH; van De Winkel JG
    Immunol Today; 2000 Aug; 21(8):391-7. PubMed ID: 10916142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging therapeutic role of antibody mixtures.
    Robak T
    Expert Opin Biol Ther; 2013 Jul; 13(7):953-8. PubMed ID: 23646883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in bispecific biotherapeutics for the treatment of cancer.
    May C; Sapra P; Gerber HP
    Biochem Pharmacol; 2012 Nov; 84(9):1105-12. PubMed ID: 22858161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity.
    Mihaylova N; Voynova E; Tchorbanov A; Dolashka-Angelova P; Bayry J; Devreese B; Kaveri S; Vassilev T
    Mol Immunol; 2009 Nov; 47(1):123-30. PubMed ID: 19243823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD30 antibody-based therapy.
    Koon HB; Junghans RP
    Curr Opin Oncol; 2000 Nov; 12(6):588-93. PubMed ID: 11085459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in cellular therapy: 6th International Symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany.
    Ullrich E; Bosch J; Aigner M; Voelkl S; Kroeger I; Hoffmann P; Kreutz M; Dudziak D; Gerbitz A
    Cancer Immunol Immunother; 2012 Mar; 61(3):433-43. PubMed ID: 22200930
    [No Abstract]   [Full Text] [Related]  

  • 13. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical applications of immunosequencing.
    Bardwell B; Bay J; Colburn Z
    Curr Res Transl Med; 2024 Sep; 72(3):103439. PubMed ID: 38447267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy.
    Schirrmacher V; Haas C
    Adv Exp Med Biol; 1998; 451():251-7. PubMed ID: 10026882
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bispecific antibodies in hematology and oncology].
    Repp R; Valerius T; Bargou R
    Internist (Berl); 2001 Jun; 42(6):854-9. PubMed ID: 11449632
    [No Abstract]   [Full Text] [Related]  

  • 18. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4th Australasian vaccines and immunotherapeutic development meeting.
    Engwerda C; Belz G
    Immunol Cell Biol; 2012 Nov; 90(10):921-4. PubMed ID: 23190698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.